Rhythm Pharmaceuticals Inc Stock News

BOSTON, March 01, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company committed to transforming the care of people living with rare genetic diseases of obesity, today announced that David Meeker, M.D., Chair, Chief Executive Officer and President, will participate in a fireside chat at the Cowen & Co. 42 nd Annual Health Care Conference on Tuesday, March 8, 2022 at 10:30 a.m. ET.

Rhythm Pharmaceuticals, Inc. (RYTM) CEO David Meeker on Q4 2021 Results - Earnings Call Transcript

BOSTON, March 01, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company committed to transforming the care of people living with rare genet

Rhythm Pharmaceuticals press release (RYTM): Q4 GAAP EPS of -$0.85 beats by $0.06.Revenue of $1.82M beats by $0.12M.

-- Preparations continue for U.S. commercial launch in June 2022 in BBS and Alström syndrome, pending FDA approval -- -- First commercial sales of IMCIVREE in Germany and France expected in 2Q2022 –

Rhythm Pharmaceuticals, Inc. (RYTM) delivered earnings and revenue surprises of 15% and 6.26%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the s

Rhythm Pharmaceuticals (NASDAQ:RYTM) is scheduled to announce Q4 earnings results on Tuesday, March 1st, before market open.The consensus EPS Estimate is -$0.93 and the consensus…

The FDA has extended the review period for Rhythm Pharmaceuticals Inc''s (NASDAQ: RYTM ) supplemental marketing application for Imcivree (setmelanotide) for obesity and control of hunger with Bardet-Biedl Syndrome (BBS) or Alström syndrome. The Prescription Drug User Fee Act (PDUFA) goal date has been revised to June 16, 2022, from March 16 . FDA requested additional subgroup analyses of the … Full story available on Benzinga.com

Lantheus LNTH +34%. Evolent Health (EVH) +18%. Orphazyme (ORPH) -36%. Rhythm Pharmaceuticals RYTM -24%.

Rhythm Pharmaceuticals (RYTM) is trading ~8% lower in the pre-market Thursday after the commercial-stage biopharma company announced that the U.S

-- FDA sets updated PDUFA goal date of June 16, 2022 -- -- Company also announces withdrawal of proposed Alström syndrome indication from Type II variation application under review by the EMA --

BOSTON, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company committed to transforming the care of people living with rare genetic diseases of obesity, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Tuesday, March 1, 2022 to report its fourth quarter and full year 2021 financial results and provide a corporate update.